Six months after new rules for clinical trials in the UK came into effect, the Medicines and Healthcare products Regulatory Agency (MHRA) has shared encouraging results. Under these updated regulations, certain important changes to ongoing drug trials can now be approved much faster—often in just seven days. The MHRA announced this progress on October 28, 2026. The new rules, which started on April 28, 2026, were designed to make the approval process for clinical trials more flexible and efficient. They focus on balancing safety with speed, ensuring that modifications to trials don’t unnecessarily delay important medical research. One key part of these changes is called the Route B pathway. This pathway allows sponsors—companies or groups running the trials—to get approval for significant trial changes more quickly, but only if they can confirm that the changes don’t introduce new safety concerns. After a six-month trial period, the Route B pathway has proven successful. On average, it takes just three days to validate the modification request and four days to review it, resulting in a total approval time of seven days. Previously, the maximum allowed time for such approvals was 21 days. The new rules also simplify the process for starting new trials. Now, sponsors only need to submit one application that is reviewed by both the MHRA and a Research Ethics Committee (REC) at the same time. This reduces paperwork and speeds up the initial approval process. Sponsors also have up to 60 days to respond to any requests for additional information, and once they respond, the MHRA aims to make a final decision within 10 days. However, the MHRA has also highlighted some common mistakes that can slow down the process. Around 3 to 5 percent of applications fail because they are missing documents, forms aren’t signed, or files don’t meet specific requirements for digital processing. To avoid delays, the MHRA advises sponsors to double-check their submissions. They should ensure all required documents are included, with special attention to details about the investigational medicinal product (the drug being tested), how it is labeled, and how it is manufactured following good manufacturing practice (GMP) standards. The MHRA stresses that submitting complete and accurate applications is crucial to keeping the process smooth and efficient under the new framework.